CD274 and neoplasm: In this trial, the response rate was higher in the pembrolizumab combination group than in the placebo-combination group across all categories of PD-L1 tumor proportion score (≥50 [n = 132], 1–49 [n = 128], <1 [n = 127], and could not be evaluated [n = 23]).